- Home
- AQST vs DGICB Comparison
AQST vs DGICB Comparison
Compare AQST & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- DGICB
- Stock Information
- Founded
- AQST 2004
- DGICB 1986
- Country
- AQST United States
- DGICB United States
- Employees
- AQST N/A
- DGICB N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- AQST Health Care
- DGICB Finance
- Exchange
- AQST Nasdaq
- DGICB Nasdaq
- Market Cap
- AQST 502.6M
- DGICB 504.0M
- IPO Year
- AQST 2018
- DGICB N/A
- Fundamental
- Price
- AQST $3.80
- DGICB $15.06
- Analyst Decision
- AQST Strong Buy
- DGICB
- Analyst Count
- AQST 8
- DGICB 0
- Target Price
- AQST $10.38
- DGICB N/A
- AVG Volume (30 Days)
- AQST 1.5M
- DGICB 928.0
- Earning Date
- AQST 11-04-2024
- DGICB 10-24-2024
- Dividend Yield
- AQST N/A
- DGICB 4.12%
- EPS Growth
- AQST N/A
- DGICB 148.60
- EPS
- AQST N/A
- DGICB 0.74
- Revenue
- AQST $58,900,000.00
- DGICB $979,119,004.00
- Revenue This Year
- AQST $18.45
- DGICB N/A
- Revenue Next Year
- AQST N/A
- DGICB $5.78
- P/E Ratio
- AQST N/A
- DGICB $21.91
- Revenue Growth
- AQST 22.56
- DGICB 7.44
- 52 Week Low
- AQST $1.84
- DGICB $10.75
- 52 Week High
- AQST $6.23
- DGICB $16.81
- Technical
- Relative Strength Index (RSI)
- AQST 36.14
- DGICB 59.65
- Support Level
- AQST $3.56
- DGICB $14.26
- Resistance Level
- AQST $3.92
- DGICB $15.90
- Average True Range (ATR)
- AQST 0.23
- DGICB 0.53
- MACD
- AQST -0.05
- DGICB -0.02
- Stochastic Oscillator
- AQST 13.91
- DGICB 31.38
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.